Master of Public Health (M.P.H.)
Public Health
Wayne State University
2022
See all Profiles
Faculty
Faculty
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP
Assistant Professor
Department/Office
- Clinical & Administrative Pharmacy Sciences
School/College
- College of Pharmacy
Biography
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP is an assistant professor in the Department of Clinical and Administrative Pharmacy Sciences at Howard University in Washington, DC, where he holds a tenure-track appointment. He completed his Doctor of Pharmacy at Virginia Commonwealth University's School of Pharmacy, followed by a PGY1 pharmacy residency and a PGY2 specialty residency in Infectious Diseases at Boston Medical Center. He subsequently completed a postdoctoral fellowship in Infectious Diseases Outcomes Research at Wayne State University's Anti-Infective Research Laboratory, alongside a Master of Public Health in Population Health Analytics.
Rebold's clinical expertise spans acute care infectious diseases, antimicrobial stewardship, antibiotic resistance in both Gram-positive and Gram-negative organisms, HIV/AIDS pharmacotherapy, and antimicrobial pharmacokinetic/pharmacodynamic principles. He practices on the Infectious Diseases consult team at an academic medical center, where he also trains students, residents, and fellows in the fundamentals of microbiology, antimicrobials, and clinical research methodology. His research draws on real-world retrospective evidence to identify optimal treatment strategies for resistant bacterial infections and to improve patient outcomes in areas where randomized controlled trial data remain limited.
Education & Expertise
Education
Doctor of Pharmacy (Pharm.D.)
Pharmacy
Virginia Commonwealth University
2018
Bachelor of Arts (B.A.)
Biology
University of Virginia
2014
Academics
Academics
Integrated Therapeutics Lab II
Integrated Therapeutics 3
Foundations of Integrated Therapeutics
Professional Practice Readiness
Research
Research
Funding
Co-investigator: Leveraging Clinical Decision Support and Kidney Stress Biomarkers to Prevent Hospital-Acquired Acute Kidney Injury in High-Risk Populations. June 2025. ASHP Foundation Optimizing Technology Solutions Innovation Grant.
Co-investigator: Pharmacist Review of Antibiotics for Discharge. December 2021. Michigan Department of Health and Human Services.
Principal Investigator: Evaluating the Impact of Combination Therapy in Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. September 2021. AHA Postdoctoral Fellowship.
Co-investigator: Ceftazidime-Avibactam Contemporary Use at Academic Hospital Systems. July 2021.
Co-investigator: Cefiderocol for Multidrug-Resistant Non-Lactose Fermenting Gram-Negative Bacteria: A multi-center retrospective study. June 2021.
Co-investigator: Real-World Experience with Dalbavancin versus Standard-of-Care for Invasive Bloodstream Infections. April 2021.
Accomplishments
Accomplishments
ACCP Pharmacotherapy Outstanding Reviewer; October 2024
MAD-ID 2022 Award Platform Presentation
Distinguished Trainee Award (Fellow) – ACCP ID-PRN; October 2021
Publications and Presentations
Publications and Presentations
Optimizing discharge antibiotic prescribing
Discharge antibiotic prescriptions are infrequently monitored by hospital antimicrobial stewardship programs but are often guideline-discordant. Leveraging pharmacist expertise may optimize discharge antibiotic prescribing, benefiting the individual patient and public health.
This is a multicenter, quasi-experimental study of an intervention in which a pharmacist reviewed, documented and communicated standardized discharge antibiotic recommendations to the primary inpatient medical team. Patients were compared prior to intervention implementation (the preintervention group) to those after intervention implementation (the postintervention group).
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States
Health disparities affecting minority populations and resulting in poorer outcomes for disadvantaged groups have been documented in the literature. Sodium/glucose-cotransporter 2 (SGLT2i) inhibitors and GLP-1 receptor agonists (GLP-1RA) markedly decrease mortality from kidney and cardiovascular events. However, little is known about the factors and disparities that lead to differences in SGLT2i and GLP-1RA initiation across different ethnic groups. Methods: This scoping review queried databases using key terms related to disparities in the initiation of SGLT2i and GLP-1RA among high-risk populations. Relevant data from eligible studies were extracted, organized, and analyzed thematically to identify key trends and patterns in the literature. Result: Nineteen studies were included in this review. Key risk factors influencing uptake included age, provider type, race, sex, education, comorbidities, insurance, and income, with minority patients consistently showing lower rates of initiation due to systemic barriers and socioeconomic disparities. Patients who were younger, male, had higher education or income levels, and received care from specialists were more likely to use these therapies. Conclusion: The adoption of SGLT2i and GLP-1RA remains suboptimal despite their proven kidney and cardiovascular benefits. Targeted efforts to reduce socioeconomic and racial inequities based on the factors identified should be encouraged.
Real-World Applications of Imipenem-Cilastatin-Relebactam
Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL.
This was a retrospective, multicenter, observational study of patients ≥18 years old who received IMI/REL for ≥48 hours for a suspected or confirmed gram-negative infection.
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection
Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed to provide further multicenter real-world evidence on dalbavancin use as a sequential therapy for Gram-positive BSI.
One hundred fifteen patients received dalbavancin with Gram-positive BSI, defined as any positive blood culture or diagnosed with infective endocarditis, from 13 centers geographically spread across the United States between July 2015 and July 2021.
Updates in pulmonary drug-resistant tuberculosis pharmacotherapy
Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM
Drug-resistant tuberculosis (TB) is a major public health concern and contributes to high morbidity and mortality. New evidence supports the use of shorter duration, all-oral regimens, which represent an encouraging treatment strategy for drug-resistant TB. As a result, the landscape of drug-resistant TB pharmacotherapy has drastically evolved regarding treatment principles and preferred agents. This narrative review focuses on the key updates of drug-resistant TB treatment, including the use of short-duration all-oral regimens, while calling attention to current gaps in knowledge that may be addressed in future observational studies.